Head of Preclinical Drug Development
Kyle Landskroner joins Azafaros from Novartis International AG where he held the position of Director Global Integration & Separation Office since 2017. With 20+ years of experience in the pharmaceutical industry, he contributes a vast knowledge of drug development, including early-stage discovery, pharmacological sciences, pharmacokinetics, toxicology and pharmacodynamics to Azafaros. Before this, he served as Director Portfolio Management, Global Drug Development, Portfolio Strategy and Innovation, at Novartis, where he led value-driven decision analyses for the Development portfolio, various clinical projects within therapeutic area franchises and strategic reviews. From 2008 until 2012, he held the position of Senior Laboratory Head at the Department of Preclinical Drug Metabolism and Pharmacokinetics at Actelion Pharmaceuticals in areas of lysosomal storage diseases and pulmonary hypertension.
Prior to Actelion, Kyle worked for Bayer Corporation in Berkeley, California and Raleigh, North Carolina in various scientific positions, including the role of Staff Scientist within Preclinical Development, with a focus on protein therapeutics for hemophilia and other thrombotic diseases. Kyle received his Ph.D. from the College of Veterinary Medicine at North Carolina State University.